An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective

por Claxton, Lindsay, Taylor, Matthew, Soonasra, Arif, Bourret, Jeffrey A., Gerber, Robert A.
Publicado 2018

Primary Nonadherence, Associated Clinical Outcomes, and Health Care Resource Use Among Patients with Rheumatoid Arthritis Prescribed Treatment with Injectable Biologic Disease-Modi...

por Harnett, James, Wiederkehr, Daniel, Gerber, Robert, Gruben, David, Bourret, Jeffrey, Koenig, Andrew
Publicado 2016

Overview of alopecia areata for managed care and payer stakeholders in the United States

por King, Brett, Pezalla, Edmund, Fung, Selwyn, Tran, Helen, Bourret, Jeffrey A, Peeples-Lamirande, Kathleen, Takiya, Liza, Napatalung, Lynne
Publicado 2023

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States

por Claxton, Lindsay, Jenks, Michelle, Taylor, Matthew, Wallenstein, Gene, Mendelsohn, Alan M., Bourret, Jeffrey A., Singh, Amitabh, Moynagh, Dermot, Gerber, Robert A.
Publicado 2016